Cancer clinical trials in the region Grand Est
288 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lung cancer
#NCT04939610
#2023-508995-12-01
NSCLC Monotherapie
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Jazz Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
#NCT04939610
#2023-508995-12-01
Cancer du sein HR+ HER2- Monotherapie
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
#NCT04939610
#2023-508995-12-01
Cancer du sein HER2+ Monotherapie
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Lung cancer
#NCT04939610
#2023-508995-12-01
NSCLC Combinaison
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
#NCT04939610
#2023-508995-12-01
Cancer du sein triple négatif TNBC Monotherapie
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Pancreas cancer
#NCT04939610
#2023-508995-12-01
PDAC Monotherapie
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04939610
#2023-508995-12-01
Phase 1: Escalade de dose
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Brain tumors / Central nervous system tumors
Skin cancer
#NCT05706129
#2023-504254-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2
Prostate cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals